Cases of extensively drug-resistant shigella infections rose from 0% in 2011 to 8.5% in 2023, according to an April 9 CDC brief.
Shigellosis is a diarrheal illness caused by bacteria that is spread through fecal-oral transmission and sexual contact. Antibiotics are indicated for severe illness or to reduce high-risk for spread, though most cases are self-limited. Currently, there are no FDA-approved oral treatments available.
The CDC analyzed 16,788 isolated cases submitted to PulseNet between Jan. 1, 2011, and Oct. 20, 2023. Previous outbreaks of the drug-susceptible strains primarily affected children, but new data shows the drug-resistant cases mostly occurred in adults. The median age was 41 and 86.2% were men. Approximately one-third of patients were hospitalized.
All of this makes Shigella a public health threat, the brief said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
